Marshall Wace, LLP Sangamo Therapeutics, Inc Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 651,906 shares of SGMO stock, worth $312,914. This represents 0.0% of its overall portfolio holdings.
Number of Shares
651,906
Previous 337,130
93.37%
Holding current value
$312,914
Previous $343,000
25.36%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding SGMO
# of Institutions
139Shares Held
52.3MCall Options Held
2.22MPut Options Held
1.82M-
Vanguard Group Inc Valley Forge, PA9.37MShares$4.5 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.87MShares$3.3 Million0.03% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$2.26 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.17MShares$1.52 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.28MShares$1.1 Million0.0% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $75.1M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...